Evidence map›Paper›PMID 25710485›Full record

ArticlePloS one2015

Liquid-solid phase-inversion PLGA implant for the treatment of residual tumor tissue after HIFU ablation.

Juan Li, Tianyi Krupka, Jinpeng Yao, Ronghui Wang, Lin Jiang, Yang Zhou, Guoqing Zuo, Zhibiao Wang, Lili Dai, Jianli Ren and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Macroporous acrylamide phantoms improve prediction of in vivo performance of in situ forming implants.Journal of controlled release : official journal of the Controlled Release Society · 2016
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Juan LiSecond Affiliated Hospital and Ultrasound Imaging Institute, Chongqing Medical University, Chongqing, 400010, P. R. China.
Tianyi KrupkaRadiology Department, Stanford University, Stanford, California, United States of America.
Jinpeng YaoSecond Affiliated Hospital and Ultrasound Imaging Institute, Chongqing Medical University, Chongqing, 400010, P. R. China.
Ronghui WangSecond Affiliated Hospital and Ultrasound Imaging Institute, Chongqing Medical University, Chongqing, 400010, P. R. China.
Lin JiangSecond Affiliated Hospital and Ultrasound Imaging Institute, Chongqing Medical University, Chongqing, 400010, P. R. China.
Yang ZhouSecond Affiliated Hospital and Ultrasound Imaging Institute, Chongqing Medical University, Chongqing, 400010, P. R. China.
Guoqing ZuoSecond Affiliated Hospital and Ultrasound Imaging Institute, Chongqing Medical University, Chongqing, 400010, P. R. China.
Zhibiao WangCollege of Biomedical Engineering, Chongqing Medical University, Chongqing, 400016, P. R. China.
Lili DaiSecond Affiliated Hospital and Ultrasound Imaging Institute, Chongqing Medical University, Chongqing, 400010, P. R. China.
Jianli RenSecond Affiliated Hospital and Ultrasound Imaging Institute, Chongqing Medical University, Chongqing, 400010, P. R. China.
Yuanyi ZhengSecond Affiliated Hospital and Ultrasound Imaging Institute, Chongqing Medical University, Chongqing, 400010, P. R. China.
Dong WangDepartment of Ultrasound, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, 400014, P. R. China.
Chongqing Medical University · CNDalian Medical University · CNSecond Affiliated Hospital of Chongqing Medical University · CNChildren's Hospital of Chongqing Medical University · CNStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHIFU has been shown to be a more suitable alternative for the treatment of primary solid tumors and metastatic diseases than other focal heat ablation techniques due to its noninvasive and extracorporeal nature. However, similar to other focal heat ablation techniques, HIFU is still in need of refinements due to tumor recurrence.

methodsIn this work, we investigated the effectiveness of an adjunct treatment regimen using doxorubicin (DOX)-loaded, injectable, in situ-forming, and phase-inverting PLGA as the second line of defense after HIFU ablation to destroy detrimental residual tumors and to prevent tumor recurrence. All of the statistical analyses were performed using the Statistical Package for the Social Sciences 18.0 (SPSS, Inc., Chicago, IL, USA), and p<0.05 was considered statistically significant. All of the results are presented as the means ± STDEV (standard deviation). For multiple comparisons, ANOVA (differences in tumor volumes, growth rates, apoptosis, proliferation indexes, and Bcl-2 and Bax protein levels) was used when the data were normally distributed with homogenous variance, and rank sum tests were used otherwise. Once significant differences were detected, Student-t tests were used for comparisons between two groups.

resultsOur results revealed that DOX diffused beyond the ablated tissue regions and entered tumor cells that were not affected by the HIFU ablation. Our results also show that HIFU in concert with DOX-loaded PLGA led to a significantly higher rate of tumor cell apoptosis and a lower rate of tumor cell proliferation in the areas beyond the HIFU-ablated tissues and consequently caused significant tumor volume shrinkage (tumor volumes:0.26±0.1,1.09±0.76, and 1.42±0.9 cm3 for treatment, sham, and no treatment control, respectively).

conclusionsFrom these results, we concluded that the intralesional injection of DOX-loaded PLGA after HIFU ablation is significantly more effective than HIFU alone for the treatment of solid tumors.

Indexed as

High-Intensity Focused Ultrasound AblationAnimalsAntibiotics, AntineoplasticApoptosisbcl-2-Associated X ProteinDoxorubicinDrug CarriersLactic AcidMicrobubblesNeoplasm, ResidualPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerProliferating Cell Nuclear AntigenProto-Oncogene Proteins c-bcl-2RabbitsSkin NeoplasmsAntibiotics, Antineoplasticbcl-2-Associated X ProteinDoxorubicinDrug CarriersLactic AcidPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerProliferating Cell Nuclear AntigenProto-Oncogene Proteins c-bcl-2

Identifiers

PMID25710485
PMCPMC4339192
OpenAlexW2050956590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.